Verrica Pharmaceuticals(US:VRCA)2026-03-11 12:08Financial Performance - YCANTH® net revenue increased by 130% to $15.3 million in 2025, compared to $6.6 million in 2024[2][16] - Total revenue for the company reached $35.6 million in 2025, up from $7.6 million in the prior year[2] - In Q4 2025, total revenue increased to $5.092 million, up from $344, representing a growth of 1,376% year-over-year[27] - Product revenue for the year ended December 31, 2025, was $15.285 million, compared to $6.574 million in 2024, marking a 132% increase[29] - License and collaboration revenue for 2025 was $20.3 million, primarily from milestone payments and commercial supplies related to the partnership with Torii Pharmaceutical[18] Expenses and Losses - Selling, general and administrative expenses decreased by over 40% to $35.2 million in 2025, down from $58.8 million in 2024[2][18] - The company reported a net loss of $17.9 million, or $1.68 per share, for the twelve months ended December 31, 2025, compared to a net loss of $76.6 million, or $14.78 per share, for the same period in 2024[18] - Research and development expenses were $8.9 million for the full year 2025, down from $11.8 million in 2024[18] - Operating expenses for Q4 2025 totaled $12.284 million, compared to $11.754 million in Q4 2024, reflecting a 4.5% increase[27] - The net loss for Q4 2025 was $8.074 million, a significant improvement from a net loss of $16.202 million in Q4 2024[27] - The company reported a basic and diluted net loss per share of $0.57 for Q4 2025, compared to $2.41 in Q4 2024[27] Assets and Liabilities - Total assets decreased to $47.131 million as of December 31, 2025, down from $54.134 million in 2024[31] - Current liabilities were $17.322 million as of December 31, 2025, compared to $30.363 million in 2024, indicating a reduction of 42.9%[31] - The company has no outstanding debt and its cash runway is extended into the first quarter of 2027[2][4] Clinical Development - The first patient was dosed in the Phase 3 study of YCANTH for common warts in December 2025, with a second study expected to start in mid-2026[2][12] - The company is advancing VP-315 toward a Phase 3 program for basal cell carcinoma, with a 97% objective response rate observed in earlier trials[11][6] - Verrica plans to expand the clinical development of YCANTH in Europe and other international markets[25] - The company has entered a worldwide license agreement with Lytix Biopharma AS to develop VP-315 for non-melanoma skin cancers[24] Product Information - YCANTH® (VP-102) is the first FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million people in the U.S., primarily children[21][24] - The number of YCANTH dispensed applicator units grew by 99% to 51,296 in 2025, compared to 25,773 units in 2024[2]